Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant

New England Journal of Medicine

Volumn 342, Issue 16, 2000, Pages 1171-1177

  Trainer, Peter J ^a   Drake, William M ^b   Katznelson, Laurence ^c   Freda, Pamela U ^d   Herman Bonert, Vivien ^e   van der Lely, A J ^f   Dimaraki, Eleni V ^g   Stewart, Paul M ^h   Friend, Keith E ⁱ   Vance, Mary Lee ^j   Besser, G Michael ^b   Scarlett, John A ^k   Thorner, Michael O ^j   Parkinson, Craig ^a   Klibanski, Anne ^c   Powell, Jeffrey S ^d   Barkan, Ariel L ^g   Sheppard, Michael C ^h   Maldonado, Mario ⁱ   Rose, D Roderick ^l   Clemmons, David R ^l   Johannsson, Gudmundur ^m   Bengtsson, Bengt Åke ^m   Stavrou, Stavros ⁿ   Kleinberg, David L ⁿ   Cook, David M ^o   Phillips, Lawrence S ^p   Bidlingmaier, Martin ^q   Strasburger, Christian J ^q   Hackett, Suzanne ^r   Zib, Kenneth ^r   Bennett, William F ^k   Davis, Robert J ^k   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Columbia College of Physicians and Surgeons ^*  (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j UNIVERSITY OF VIRGINIA   (United States)

^k Sensus Drug Development Corporation   (United States)

^l UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^m SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁿ NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^o OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^p EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF MUNICH   (Germany)

^r Stat Works   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE RECEPTOR; GROWTH HORMONE RECEPTOR ANTAGONIST; PEGVISOMANT; UNCLASSIFIED DRUG;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FLATULENCE; GENETIC ENGINEERING; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SCORING SYSTEM; UPPER RESPIRATORY TRACT INFECTION;

EID: 0034690311     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200004203421604     Document Type: Article

References (26)

1. Swearingen B, Barker FG II, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-26.
2. Sheaves R, Jenkins P, Blackburn P, et al. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 1996;45:407-13.
3. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998;89:353-8.
4. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 1999;50:561-7.
5. Barkan AL, Halasz I, Dornfeld KJ, et al. Pituitary irradiation is ineffective in normalizing plasma insulin like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997;82:3187-91.
6. van der Lely AJ, de Herder WW, Lamberts SW. The role of radiotherapy in acromegaly. J Clin Endocrinol Metab 1997;82:3185-6.
7. Barkan AL. Acromegaly: diagnosis and therapy. Endocrinol Metab Clin North Am 1989;18:277-310.
8. Cozzi R, Attanasio R, Barausse M, et al. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 1998; 139:516-21.
9. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83:374-8.
10. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide: results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991;151:1573-8.
11. Ezzat S, Redelmeier DA, Gnehm M, Harris AG. A prospective multi-center octreotide dose response study in the treatment of acromegaly. J Endocrinol Invest 1995;18:364-9.
12. Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. J Clin Endocrinol Metab 1995; 80:2768-75. [Erratum, J Clin Endocrinol Metab 1995;80:3238.]
13. Flogstad AK, Halse J, Bakke S, et al. Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab 1997;82:23-8.
14. Lancranjan I, Atkinson AB, Sandostatin LAR Group. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Pituitary 1999;1:105-14.
15. Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334:246-54.
16. Chen WY, Wight DC, Wagner TE, Kopchick JJ. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci U S A 1990;87:5061-5.
17. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science 1992;256:1677-80.
18. Lundin P, Petersen F. The volume of pituitary macroadenomas: assessment by MR. J Comput Assist Tomogr 1992;16:519-28.
19. Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR, Wells JA. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 1991; 254:821-5.
20. Olsen K, Gehant R, Mukku V, et al. Preparation and characterization of poly(ethylene glycol)ylated human growth hormone antagonist. In: Harris J, Zalipsky S, eds. Poly(ethylcne glycol): chemistry and biological applications. Washington, D.C.: American Chemical Society, 1997:170-81.
21. Clark R, Olson K, Fuh G, et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 1996;271: 21969-77.
22. Zalipsky S, Lee C. Use of functionalized polyethylene glycols for modification of polypeptides. In: Harris JM, ed. PEG chemistry: biotechnical and biomedical applications. New York: Plenum Press, 1992:347-70.
23. Francis GE, Delgado C, Fisher D. PEG-modified proteins. In: Ahern TJ, Manning MC, eds. Stability of protein pharmaceuticals. Part B. In vivo pathways of degradation and strategies for protein stabilization. New York: Plenum Press, 1992:235-63.
24. Goffin V, Bernichtein S, Carriere O, Bennett WF, Kopchick JJ, Kelly PA. The human growth hormone antagonist B2036 does not interact with the prolactin receptor. Endocrinology 1999;140:3853-6.
25. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997;82:18-22.
26. Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism 1996;45:Suppl 1:67-71.